Telix Pharmaceuticals Limited (ASX:TLX)
Australia · Delayed Price · Currency is AUD | Market Cap | 5.28B -39.2% |
| Revenue (ttm) | 1.21B +55.6% |
| Net Income | -10.68M |
| EPS | -0.03 |
| Shares Out | 339.11M |
| PE Ratio | n/a |
| Forward PE | 689.32 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,366,262 |
| Average Volume | 2,881,478 |
| Open | 15.40 |
| Previous Close | 15.00 |
| Day's Range | 15.32 - 15.62 |
| 52-Week Range | 8.26 - 29.64 |
| Beta | 0.65 |
| RSI | 66.43 |
| Earnings Date | Aug 19, 2026 |
About Telix Pharmaceuticals
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ... [Read more]
News
Telix Presents Phase 2 OPTIMAL-PSMA Dosimetry Data For TLX597-Tx In Prostate Cancer Treatment
(RTTNews) - Telix Pharmaceuticals Limited (TLX), a commercial-stage biopharmaceutical company, on Thursday presented dosimetry data from the Phase 2 OPTIMAL-PSMA trial for TLX597-Tx in treating metast...
TLX101-Px (Pixlumi®) MAA Accepted in Europe
MELBOURNE, Australia and INDIANAPOLIS, May 01, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the marketing authorization application (MAA...
Telix Pharmaceuticals Transcript: Status update
Second-generation PSMA-targeted therapy TLX597-Tx shows promising tumor targeting with minimal off-target toxicity, supporting dose intensification and adaptive dosing strategies in advanced prostate cancer. Early OPTIMAL-PSMA trial data indicate deep responses and good tolerability, with future studies aiming for durable remissions and improved quality of life.
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
MELBOURNE, Australia and INDIANAPOLIS, April 30, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces dosimetry results from the randomized Phase 2 O...
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
MELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) announces an educational webinar exploring the evolution of PSM...
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
MELBOURNE, Australia and INDIANAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that safety and tolerability data from the Pros...
Telix Pharma Doses First Patient In Phase 3 IPAX BrIGHT Trial Of TLX101-Tx; Prices $600 Mln Bonds
(RTTNews) - Telix Pharmaceuticals Ltd (TLX, TLZ.AX), a commercial-stage biopharmaceutical company, announced on Wednesday that it has dosed the first patient in the pivotal Phase 3 IPAX BrIGHT trial e...
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient has been dosed with TLX1...
Fundies feast on Telix Pharmaceuticals block amid $US550m convertible
The bock trade, expected to be finalised overnight, is part of a so-called delta hedging placement usually seen around convertible bonds.
Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs
Telix Pharmaceuticals Limited (NASDAQ: TLX) shares are up during Monday’s premarket session following a significant collaboration announcement with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Reg...
Regeneron (REGN) Partners with Telix Pharmaceuticals
Regeneron (REGN) Partners with Telix Pharmaceuticals
Regeneron (REGN) Partners with Telix Pharmaceuticals for Innovative Radiopharmaceuticals
Regeneron (REGN) Partners with Telix Pharmaceuticals for Innovative Radiopharmaceuticals
Regeneron Pharma Partners Telix Pharma To Jointly Develop Radiopharmaceutical Therapies
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Telix Pharmaceuticals Ltd. (TLX, TLX.AX) announced Monday a collaboration to jointly develop and commercialize next generation radiopharmaceutica...
Telix and Regeneron Announce Strategic Radiopharma Collaboration
MELBOURNE, Australia and INDIANAPOLIS and TARRYTOWN, N.Y., April 13, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and Regeneron Pharmaceuticals, Inc. (NASDAQ...
Telix And Regeneron Partner To Advance Next-Generation Radiopharmaceutical Therapies
(RTTNews) - Telix Pharmaceuticals Limited (TLX, TLX.AX) and Regeneron Pharmaceuticals, Inc. (REGN) have announced a collaboration to jointly develop and commercialize next-generation radiopharmaceutic...
Telix Pharmaceuticals Shares Jump 7% on FDA Nod for Brain Cancer Imaging Agent Amid Strong Revenue Momentum
MELBOURNE, Australia — Telix Pharmaceuticals Ltd. shares surged more than 7% Friday as the Australian radiopharmaceutical company received a key regulatory boost in the United States, highlighting its...
Telix Seeks Reset With FDA Filing While Sales Growth Holds Steady
The agency assigned a PDUFA goal date of September 11.
Telix Pharmaceuticals (TLX) Sees 7% Gain Following FDA Acceptance of Imaging Agent
Telix Pharmaceuticals (TLX) Sees 7% Gain Following FDA Acceptance of Imaging Agent
ASX 200 Top Gainers: Telix Pharma Jumps 3.23% on FDA Nod as Healthcare Leads Mixed Session Amid Oil Rebound
SYDNEY — Telix Pharmaceuticals Ltd (ASX: TLX) led the S&P/ASX 200 gainers Friday with a 3.23 percent surge to $14.08 after the U.S. Food and Drug Administration accepted its resubmitted New Drug Appli...
FDA Accepts NDA for TLX101-Px (Pixclara®)
MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Adm...
Telix Strengthens Board with Additional Director Appointments
MELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces two additional Non-Executive Director (NED) app...
Why Is Telix Pharma Stock Soaring Tuesday?
Wedbush analyst David Nierengarten reiterated an Outperform rating on the stock and maintained a $22 price target, underscoring confidence in Telix's growth trajectory.
Telix Pharmaceuticals Stock Rises 5% Over Strong Revenue Growth In Q1
(RTTNews) - Shares of Telix Pharmaceuticals Limited (TLX) are moving up about 5 percent after the company announced first-quarter financial results, which saw 24% increase in revenue to $230 million f...
Telix Pharma Reports 24% Revenue Growth In Q1; Stock Up
(RTTNews) - Telix Pharmaceuticals Limited (TLX), a commercial-stage company, reported first-quarter results on Monday, reflecting 24% revenue growth compared to the prior year. In addition, the firm r...
Telix Pharmaceuticals Q1 Group Revenue Rises; Stock Up
(RTTNews) - Telix Pharmaceuticals Limited (TLX, TLX.AX) reported that its group revenue for the first quarter of fiscal year 2016 increased about 24% to US$230 million, from US$186 million last year.